Fumihiko Kato1, Hiroyuki Daiko1, Jun Kanamori1, Yoshihiro Inamoto2, Takahiro Fukuda2, Koji Hayashi3, Yuji Tachimori1,4, Kazuo Koyanagi5,6. 1. Department of Esophageal Surgery, National Cancer Center Hospital, Chuo-ku, Japan. 2. Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Chuo-ku, Japan. 3. Department of Surgery, Ota Memorial Hospital, Ota, Japan. 4. Cancer Care Center, Kawasaki Saiwai Hospital, Kawasaki, Japan. 5. Department of Esophageal Surgery, National Cancer Center Hospital, Chuo-ku, Japan. kkoyanagi@tsc.u-tokai.ac.jp. 6. Department of Gastroenterological Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. kkoyanagi@tsc.u-tokai.ac.jp.
Abstract
BACKGROUND: The number of long-term survivors after allogeneic hematopoietic stem cell transplantation (HSCT) has increased recently. Esophageal squamous cell carcinoma occurs at a particularly high incidence as a secondary cancer after HSCT. However, standard treatment for these patients has not been established yet. The objectives of this study were to investigate outcomes of esophagectomy for esophageal carcinoma developed in HSCT patients, and to provide the appropriate perioperative management. METHODS: Ten HSCT patients underwent esophagectomy for esophageal squamous cell carcinoma between December 2007 and September 2017 at the National Cancer Center Hospital. The surgical outcomes and long-term prognosis of these patients were reviewed retrospectively. RESULTS: In the former group, 5 of the 7 patients (71.4%) developed pneumonia after esophagectomy, with two of them requiring intubation because of respiratory failure. None of the three patients of the latter group, who received broad-spectrum antibiotics for more than 7 days after the surgery, developed any postoperative complications. The estimated survival probability of these patients at 5 years after the surgery was 53.3%. CONCLUSIONS: HSCT patients have an extremely high risk of developing pneumonia after esophagectomy, and the condition can easily become serious. Therefore, broad-spectrum antibiotics should be administered prophylactically to prevent severe pneumonia during the perioperative period in these patients.
BACKGROUND: The number of long-term survivors after allogeneic hematopoietic stem cell transplantation (HSCT) has increased recently. Esophageal squamous cell carcinoma occurs at a particularly high incidence as a secondary cancer after HSCT. However, standard treatment for these patients has not been established yet. The objectives of this study were to investigate outcomes of esophagectomy for esophageal carcinoma developed in HSCT patients, and to provide the appropriate perioperative management. METHODS: Ten HSCT patients underwent esophagectomy for esophageal squamous cell carcinoma between December 2007 and September 2017 at the National Cancer Center Hospital. The surgical outcomes and long-term prognosis of these patients were reviewed retrospectively. RESULTS: In the former group, 5 of the 7 patients (71.4%) developed pneumonia after esophagectomy, with two of them requiring intubation because of respiratory failure. None of the three patients of the latter group, who received broad-spectrum antibiotics for more than 7 days after the surgery, developed any postoperative complications. The estimated survival probability of these patients at 5 years after the surgery was 53.3%. CONCLUSIONS: HSCT patients have an extremely high risk of developing pneumonia after esophagectomy, and the condition can easily become serious. Therefore, broad-spectrum antibiotics should be administered prophylactically to prevent severe pneumonia during the perioperative period in these patients.
Authors: Alois Gratwohl; Helen Baldomero; Mahmoud Aljurf; Marcelo C Pasquini; Luis Fernando Bouzas; Ayami Yoshimi; Jeff Szer; Jeff Lipton; Alvin Schwendener; Michael Gratwohl; Karl Frauendorfer; Dietger Niederwieser; Mary Horowitz; Yoshihisa Kodera Journal: JAMA Date: 2010-04-28 Impact factor: 56.272
Authors: Y Atsuta; R Suzuki; T Yamashita; T Fukuda; K Miyamura; S Taniguchi; H Iida; T Uchida; K Ikegame; S Takahashi; K Kato; K Kawa; T Nagamura-Inoue; Y Morishima; H Sakamaki; Y Kodera Journal: Ann Oncol Date: 2014-01-07 Impact factor: 32.976
Authors: G Socié; C Scieux; E Gluckman; T Soussi; C Clavel; P Saulnier; P Birembault; J Bosq; F Morinet; A Janin Journal: Transplantation Date: 1998-09-15 Impact factor: 4.939
Authors: K Mori; Y Yamagata; S Aikou; M Nishida; T Kiyokawa; K Yagi; H Yamashita; S Nomura; Y Seto Journal: Dis Esophagus Date: 2015-03-23 Impact factor: 3.429